Pick disease
MONDO:0008243
A rare neurodegenerative disorder leading to dementia. It is characterized by frontotemporal lobar degeneration with accumulation of tau proteins which form Pick bodies.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Frontotemporal dementia
Frontotemporal dementia (FTD), also known as frontotemporal degeneration, and historically as Pick's disease, is a family of neurodegenerative disorders, caused by frontotemporal lobar degeneration that affects the frontal and temporal lobes. The FTD family includes behavioral variant FTD, primary progressive aphasia (PPA) and its semantic and nonfluent/agrammatic variants, primary progressive apraxia of speech (PPAOS), progressive supranuclear palsy, and corticobasal syndrome. Through a mutual risk gene, FTD and amyotrophic lateral sclerosis (ALS) share a clinical spectrum, where symptoms of both disorders can co-occur. Symptoms of FTD will typically match a specific disorder at first, though symptoms of other disorders will begin to show as the disease progresses to different areas of the brain. FTD disorders are a common young-onset dementia occurring under the age of 60. Approximately 60% of people diagnosed with FTD have no known cause and no family history of FTD or related conditions; this is known as sporadic FTD. While environmental causes and unidentified gene variants are suspected causes of sporadic FTD, research in this area is still ongoing. When people have a family history of FTD, other dementias, or conditions like depression or anxiety, it is referred to as familial FTD, and roughly 20% have an underlying genetic basis. Variants in three genes are responsible for most genetic FTD. Notably, in about 10% of people with seemingly sporadic FTD, a genetic variant is identified. FTD diagnosis currently relies on clinical examination based on the signs and sym...
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.